ACE-232 / Acerand Therap - LARVOL DELTA

Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=67 | Recruiting | Sponsor: Acerand Therapeutics (Hong Kong) Limited | Not yet recruiting ➔ Recruiting

Enrollment open • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Discovery of ACE-232: a novel and highly potent non-steroidal CYP11A1 inhibitor (AACR 2025) - "In castrated mouse models, ACE-232 showed equal or superior efficacy in inhibiting tumor growth at 0.3 mg/kg QD in both VCaP and enzalutamide-resistant xLNCaP models, compared to ODM-208 at 30 mg/kg BID. GLP toxicology studies demonstrated a wide safety margin in both rats and dogs, with primary effects observed in the endocrine and reproductive organs, consistent with CYP11A1 inhibition. Based on these findings, an IND filing for ACE-232 with the FDA is planned for December 2024."

Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Phase 1 Study of ACE-232 to Treat Patients with Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=67 | Not yet recruiting | Sponsor: Acerand Therapeutics (Hong Kong) Limited

New P1 trial • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor